Predicting skeletal complications in metastatic breast cancer raises challenges.
Van Poznak
Catherine
C
University of Michigan, Ann Arbor, MI, USA. cvanpoz@umich.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D010146:Pain / Q000209:etiology* / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D013117:Spinal Cord Compression / Q000209:etiology* / Q000517:prevention & control; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid